Literature DB >> 17542529

Stereotactic radiation treatment for recurrent nonbenign meningiomas.

Carlos A Mattozo1, Antonio A F De Salles, Ivan A Klement, Alessandra Gorgulho, David McArthur, Judith M Ford, Nzhde Agazaryan, Daniel F Kelly, Michael T Selch.   

Abstract

OBJECT: The authors analyzed the results of stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) for the treatment of recurrent meningiomas that were described at initial resection as showing aggressive, atypical, or malignant features (nonbenign).
METHODS: Twenty-five patients who underwent SRS and/or SRT for nonbenign meningiomas between December 1992 and August 2004 were included. Thirteen of these patients underwent treatment for multiple primary or recurrent lesions. In all, 52 tumors were treated. All histological sections were reviewed and reclassified according to World Health Organization (WHO) 2000 guidelines as benign (Grade I), atypical (Grade II), or anaplastic (Grade III) meningiomas. The median follow-up period was 42 months. Seventeen (68%) of the cases were reclassified as follows: WHO Grade I (five cases), Grade II (11 cases), and Grade III (one case). Malignant progression occurred in eight cases (32%) during the follow-up period; these cases were considered as a separate group. The 3-year progression-free survival (PFS) rates for the Grades I, II, and III, and malignant progression groups were 100, 83, 0, and 11%, respectively (p < 0.001). In the Grade II group, the 3-year PFS rates for patients treated with SRS and SRT were 100 and 33%, respectively (p = 0.1). After initial treatment, 22 new tumors required treatment using SRS or SRT; 17 (77%) of them occurred inside the original resection cavity. Symptomatic edema developed in one patient (4%).
CONCLUSIONS: Stereotactic radiation treatment provided effective local control of "aggressive" Grade I and Grade II meningiomas, whereas Grade III lesions were associated with poor outcome. The outcome of cases in the malignant progression group was intermediate between that of the Grade II and Grade III groups, with the lesions showing a tendency toward malignancy.

Entities:  

Mesh:

Year:  2007        PMID: 17542529     DOI: 10.3171/jns.2007.106.5.846

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  16 in total

1.  Stereotactic radiation therapy for skull base recurrences: Is a salvage approach still possible?

Authors:  Marco Krengli; Giuseppina Apicella; Letizia Deantonio; Marina Paolini; Laura Masini
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-04

Review 2.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Authors:  Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

Review 3.  A review of malignant meningiomas: diagnosis, characteristics, and treatment.

Authors:  Simon Hanft; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2010-08-21       Impact factor: 4.130

4.  Papillary meningioma of the jugular foramen: A case report.

Authors:  Ying Yu; Haiyang Xu; Yubo Wang; Gang Zhao
Journal:  Oncol Lett       Date:  2015-10-08       Impact factor: 2.967

5.  Recurrent meningioma with malignant transformation: a case report and literature review.

Authors:  Junwen Wang; Lei Wang; Bo Luo; Zhi Chen; Zuojun Xiong; Mingbo Fang; Jun Li
Journal:  Int J Clin Exp Med       Date:  2015-09-15

6.  Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.

Authors:  Derek R Johnson; David W Kimmel; Patrick A Burch; Terrence L Cascino; Caterina Giannini; Wenting Wu; Jan C Buckner
Journal:  Neuro Oncol       Date:  2011-05       Impact factor: 12.300

7.  Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease.

Authors:  Susan C Pannullo; Justin F Fraser; Jennifer Moliterno; William Cobb; Philip E Stieg
Journal:  J Neurooncol       Date:  2010-12-09       Impact factor: 4.130

8.  Reirradiation of recurrent meningioma.

Authors:  Andrzej P Wojcieszynski; Nitin Ohri; David W Andrews; James J Evans; Adam P Dicker; Maria Werner-Wasik
Journal:  J Clin Neurosci       Date:  2012-07-10       Impact factor: 1.961

9.  Predictors of Treatment Response and Survival Outcomes in Meningioma Recurrence with Atypical or Anaplastic Histology.

Authors:  Muhammad O Chohan; Christopher T Ryan; Ranjodh Singh; Ryan M Lanning; Anne S Reiner; Marc K Rosenblum; Viviane Tabar; Philip H Gutin
Journal:  Neurosurgery       Date:  2018-06-01       Impact factor: 4.654

10.  Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma.

Authors:  Ayal A Aizer; Nils D Arvold; Paul Catalano; Elizabeth B Claus; Alexandra J Golby; Mark D Johnson; Ossama Al-Mefty; Patrick Y Wen; David A Reardon; Eudocia Q Lee; Lakshmi Nayak; Mikael L Rinne; Rameen Beroukhim; Stephanie E Weiss; Shakti H Ramkissoon; Malak Abedalthagafi; Sandro Santagata; Ian F Dunn; Brian M Alexander
Journal:  Neuro Oncol       Date:  2014-06-02       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.